New estimates of the costs of adverse events in patients with cancer

The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	PloS one Ročník 20; číslo 9; s. e0332703
Hlavní autoři:	Patel, Achal, Schuldt, Robert, Sussell, Jesse
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Public Library of Science 29.09.2025 Public Library of Science (PLoS)
Témata:	Adult Adverse and side effects Adverse events Aged Allergic reactions Allergies Availability Cancer Cancer therapies Care and treatment Chronic lymphocytic leukemia Cost assessments Costs Critical components Data acquisition Drug-Related Side Effects and Adverse Reactions - economics Drugs Economic models Economics Estimates Female Forecasts and trends Health Care Costs Health care expenditures Health care policy Health problems Health services Hodgkin's lymphoma Humans Leukemia Lymphatic leukemia Lymphoma Male Medical diagnosis Medical economics Medicare Melanoma Middle Aged Multiple myeloma Nausea Neoplasms - drug therapy Neoplasms - economics Oncology Patients Photosensitivity Regulatory approval Tumors United States United States Italy
ISSN:	1932-6203, 1932-6203
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental costs of AEs across 13 cancer types by applying the most current diagnosis schema (International Statistical Classification of Diseases and Related Health Problems [ICD-10]) to patients diagnosed between 2016 and 2022. Data were acquired from US insurance claims and included adult patients who were diagnosed and treated for breast, pancreatic, bladder, lung, prostate, colorectal, skin, liver, head and neck, non-Hodgkin lymphoma, follicular lymphoma, multiple myeloma, or chronic lymphocytic leukemia cancer. We selected 54 AEs for analysis based on their frequency of occurrence, relevance based on severity, and availability of ICD-10 diagnostic codes. We matched patient treatment episodes (the period from initiation of a distinct treatment regimen until discontinuation, change of treatment, or end of data availability) for patients experiencing a specific AE to treatment episodes of similar patients not experiencing that same AE in a 1:1 ratio. We generated estimates for AEs of any severity, severe AEs, and individual tumor types. Our analyses evaluate 392,566 treatment episodes from 110,791 patients. In pooled analyses across tumor types, incremental costs for AEs of any severity (with ≥ 100 treatment episodes) ranged from - $488 for photosensitivity to $29,331 for allergic reaction. Incremental costs for severe AEs (with ≥ 50 treatment episodes) ranged from $16 for dizziness to $18,841 for gastrointestinal bleeding. This study provides a comprehensive assessment of the economic burden of AEs in cancer care and generates a range of estimates to be used as inputs in future economic models.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0332703